Direkt zum Inhalt
Merck

EHU123791

MISSION® esiRNA

targeting human PRKDC

Slide 1 of 1
Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Preise und Verfügbarkeit sind derzeit nicht verfügbar.

Über diesen Artikel

NACRES:
NA.51
UNSPSC Code:
41105324

Wichtige Dokumente

Gesamtdokumentation anzeigen

Fortfahren mit

Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

Produktname

MISSION® esiRNA, targeting human PRKDC

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CTTCGACTTGCGTGTGATGTTGATCAGGTGACAAGGCAACTGTATGAGCCACTAGTTATGCAGCTGATTCACTGGTTCACTAACAACAAGAAATTTGAAAGTCAGGATACTGTTGCCTTACTAGAAGCTATATTGGATGGAATTGTGGACCCTGTTGACAGTACTTTAAGAGATTTTTGTGGTCGGTGTATTCGAGAATTCCTTAAATGGTCCATTAAGCAAATAACACCACAGCAGCAGGAGAAGAGTCCAGTAAACACCAAATCGCTTTTCAAGCGACTTTATAGCCTTGCGCTTCACCCCAATGCTTTCAAGAGGCTGGGAGCATCACTTGCCTTTAATAATATCTACAGGGAATTCAGGGAAGAAGAGTCTCTGGTGGAACAGTTTGTGTTTGAAGCCTTGGTGATATACATGGAGAGTCTGGCCTTAGCACATGC

Ensembl | human accession no.

ENSG00000121031

NCBI accession no.

NM_001081640

shipped in

ambient

storage temp.

−20°C

Quality Level

100

Gene Information

human ... PRKDC(5591), PRKDC(5591)

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 4

Dieser Artikel
EHU118481EHU145811EHU151001
MISSION® esiRNA targeting human PRKDC

Sigma-Aldrich

EHU123791

MISSION® esiRNA

MISSION® esiRNA targeting human PRKCE

Sigma-Aldrich

EHU118481

MISSION® esiRNA

MISSION® esiRNA targeting human PRKG1

Sigma-Aldrich

EHU145811

MISSION® esiRNA

MISSION® esiRNA targeting human LENEP

Sigma-Aldrich

EHU151001

MISSION® esiRNA

esiRNA cDNA target sequence

CTTCGACTTGCGTGTGATGTTGATCAGGTGACAAGGCAACTGTATGAGCCACTAGTTATGCAGCTGATTCACTGGTTCACTAACAACAAGAAATTTGAAAGTCAGGATACTGTTGCCTTACTAGAAGCTATATTGGATGGAATTGTGGACCCTGTTGACAGTACTTTAAGAGATTTTTGTGGTCGGTGTATTCGAGAATTCCTTAAATGGTCCATTAAGCAAATAACACCACAGCAGCAGGAGAAGAGTCCAGTAAACACCAAATCGCTTTTCAAGCGACTTTATAGCCTTGCGCTTCACCCCAATGCTTTCAAGAGGCTGGGAGCATCACTTGCCTTTAATAATATCTACAGGGAATTCAGGGAAGAAGAGTCTCTGGTGGAACAGTTTGTGTTTGAAGCCTTGGTGATATACATGGAGAGTCTGGCCTTAGCACATGC

esiRNA cDNA target sequence

AGCTTTGGCAAGGTCATGTTGGCAGAACTCAAGGGCAAAGATGAAGTATATGCTGTGAAGGTCTTAAAGAAGGACGTCATCCTTCAGGATGATGACGTGGACTGCACAATGACAGAGAAGAGGATTTTGGCTCTGGCACGGAAACACCCGTACCTTACCCAACTCTACTGCTGCTTCCAGACCAAGGACCGCCTCTTTTTCGTCATGGAATATGTAAATGGTGGAGACCTCATGTTTCAGATTCAGCGCTCCCGAAAATTCGACGAGCCTCGTTCACGGTTCTATGCTGCAGAGGTCACATCGGCCCTCATGTTCCTCCACCAGCATGGAGTCATCTACAGGGATTTGAAACTGGACAACATCCTTCTGGATGCAGAAGGTCACTGCAAGCTGGCTGACTTCGGGATGTGCAAGGAAGGGATTCTGAATGGTGTGACGACCAC

esiRNA cDNA target sequence

CCTGCCTTGTGATTGACAGAGACTCTTTTAAACATTTGATTGGAGGGCTGGATGATGTTTCTAATAAAGCATATGAAGATGCAGAAGCTAAAGCAAAATATGAAGCTGAAGCGGCTTTCTTCGCCAACCTGAAGCTGTCTGATTTCAACATCATTGATACCCTTGGAGTTGGAGGTTTCGGACGAGTAGAACTGGTCCAGTTGAAAAGTGAAGAATCCAAAACGTTTGCAATGAAGATTCTCAAGAAACGTCACATTGTGGACACAAGACAGCAGGAGCACATCCGCTCAGAGAAGCAGATCATGCAGGGGGCTCATTCCGATTTCATAGTGAGACTGTACAGAACATTTAAGGACAGCAAATATTTGTATATGTTGATGGAAGCTTGTCTAGGTGGAGAGCTCTGGACCATTCTCAGGGA

esiRNA cDNA target sequence

CCAAACCCTACCCTTCTTCCTCGGAGGGGCCCCTCGAGACACTGGGCTGCGGGTGCCTGTCATTAAGATGGGCACAGGGTGGGAGGGCTTCCAGCGGACCCTGAAGGAAGTCGCCTACATCCTCCTCTGCTGCTGGTGTATCAAGGAACTGCTGGATTAATGGTAGCAGGGAACTGCCTCCTCTCCCCACCAGCACCATGGCTGGCATCGCTCAGCCCCCAGCCCAATTGCCATCAAGACTCCTGAAGCCAGCTGTGCTTGACCAAGGATGGGCCATAAACAATGAGTAAACAGTAAAGTGTGGATCCTGCTTTGAGCTGTGTCATCTAGCAGACCTGCCTCATCTCTGAGCCTCCTTCATTCCCAACCCCTGCCTCTGGTGGACCTCTGGTGGGCAGGAGCTTGGACTGCTCTGGCTAGGACCCCAGTAAGATTGTGGCAAGACCTGG

Ensembl | human accession no.

ENSG00000121031

Ensembl | human accession no.

ENSG00000171132

Ensembl | human accession no.

ENSG00000185532

Ensembl | human accession no.

ENSG00000163352

Gene Information

human ... PRKDC(5591), PRKDC(5591)

Gene Information

human ... PRKCE(5581), PRKCE(5581)

Gene Information

human ... PRKG1(5592), PRKG1(5592)

Gene Information

human ... LENEP(55891), LENEP(55891)

product line

MISSION®

product line

MISSION®

product line

MISSION®

product line

MISSION®

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

NCBI accession no.

NM_001081640

NCBI accession no.

NM_005400

NCBI accession no.

NM_001098512

NCBI accession no.

NM_018655

General description

MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Lagerklasse

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
VDV
ACIU
JUU
KDT
DMS

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Sonia Paget et al.
Oncotarget, 8(2), 2916-2935 (2016-12-10)
The tumor suppressor gene HIC1 (Hypermethylated In Cancer 1) encodes a transcriptional repressor mediating the p53-dependent apoptotic response to irreparable DNA double-strand breaks (DSBs) through direct transcriptional repression of SIRT1. HIC1 is also essential for DSB repair as silencing of
Xing-Mei Liang et al.
Acta pharmacologica Sinica, 42(4), 648-654 (2021-01-09)
The third-generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), represented by osimertinib, has achieved remarkable clinical outcomes in the treatment of non-small-cell lung cancer (NSCLC) with EGFR mutation. However, resistance eventually emerges in most patients and the underlying
Lin Jia et al.
The Journal of pathology, 243(2), 255-266 (2017-08-05)
Endostatin was discovered as an endogenous angiogenesis inhibitor with broad-spectrum antitumour activities. Although clinical efficacy was observed when endostatin was combined with standard chemotherapy for non-small cell lung cancer (NSCLC), as well as other cancer types, the specific mechanisms underlying
Emanuela Dylgjeri et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(18), 5623-5637 (2019-07-04)
DNA-dependent protein kinase catalytic subunit (DNA-PK) is a pleiotropic kinase involved in DNA repair and transcriptional regulation. DNA-PK is deregulated in selected cancer types and is strongly associated with poor outcome. The underlying mechanisms by which DNA-PK promotes aggressive tumor
Sara Sofia Deville et al.
Cancers, 12(7) (2020-07-02)
The treatment resistance of cancer cells is a multifaceted process in which DNA repair emerged as a potential therapeutic target. DNA repair is predominantly conducted by nuclear events; yet, how extra-nuclear cues impact the DNA damage response is largely unknown.
Alle zugehörigen Dokumente anzeigen

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung